- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Interventions
- AZD8931, anastrozole, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Lake Success, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 166
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
- Interventions
- Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 884 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
- Interventions
- Samuraciclib, Fulvestrant
- Drug
- Lead sponsor
- Carrick Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Lowell, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced HR+/HER2- Breast Cancer
- Interventions
- IEV407, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Dallas, Texas
- Conditions
- Hormone-receptor Positive Breast Cancer
- Interventions
- exemestane and pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
- Interventions
- Felmetatug Vedotin, Pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more
- Conditions
- Breast Neoplasms, Neoplasms, Hormone-Dependent
- Interventions
- Atamestane, Toremifene, Letrozole, Aromatase inhibition, Estrogen receptor blocker, Hormone therapy, Endocrine therapy, Antiestrogen therapy
- Drug · Procedure
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 842 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 49
- States / cities
- Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more
- Conditions
- Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
- Interventions
- PRT2527
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Interventions
- non-interventional
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 301
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 224 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- fulvestrant, anastrozole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years to 100 Years · Female only
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 5
- States / cities
- Frederick, Maryland • St Louis, Missouri • Teaneck, New Jersey + 2 more
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
- Interventions
- XL092, Atezolizumab, Avelumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 40
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
- Interventions
- GZ17-6.02, Capecitabine
- Drug
- Lead sponsor
- Genzada Pharmaceuticals USA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Alpelisib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more
- Conditions
- Breast Cancer
- Interventions
- Tesetaxel and Capecitabine, Capecitabine
- Drug
- Lead sponsor
- Odonate Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 685 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 90
- States / cities
- Chandler, Arizona • Goodyear, Arizona • Tucson, Arizona + 81 more
- Conditions
- Breast Cancer
- Interventions
- GDC-0810, LHRH Agonist, Palbociclib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 8
- States / cities
- San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Advanced Breast Cancer, Early Breast Cancer
- Interventions
- ZOLADEX
- Drug
- Lead sponsor
- TerSera Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 23
- States / cities
- Hot Springs, Arkansas • Washington D.C., District of Columbia • Ocoee, Florida + 19 more
- Conditions
- HER2-positive Breast Cancer, Advanced Breast Cancer
- Interventions
- Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Miami, Florida • Boston, Massachusetts
- Conditions
- Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
- Interventions
- OP-1250
- Drug
- Lead sponsor
- Olema Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more
- Conditions
- Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
- Interventions
- GTAEXS617, SoC
- Drug
- Lead sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more